Company profile for Affinia Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties. We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products w...
At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties. We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products with an initial focus on muscle and central nervous system (CNS) diseases with significant unmet need.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Waltham, Massachusetts 02451, US
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251014387033/en/Affinia-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences

BUSINESSWIRE
14 Oct 2025

https://www.businesswire.com/news/home/20251007974424/en/Affinia-Therapeutics-Announces-Series-C-Financing-to-Advance-New-Class-of-Gene-Therapies-Intended-to-Provide-Improved-Safety-and-Efficacy

BUSINESSWIRE
07 Oct 2025

https://www.businesswire.com/news/home/20250603460821/en/Affinia-Therapeutics-and-DCM-Foundation-Announce-Partnership-to-Increase-Awareness-About-BAG3-Dilated-Cardiomyopathy-and-Critical-Need-for-Genetic-Testing-to-Help-Save-Lives

BUSINESSWIRE
03 Jun 2025

https://www.businesswire.com/news/home/20250513343280/en/Affinia-Therapeutics-Presents-New-Data-on-its-Lead-AFTX-201-Program-in-BAG3-Dilated-Cardiomyopathy-BBB-Penetrant-AAV-Capsids-and-Proprietary-Manufacturing-Technology-at-the-28th-American-Society-of-Gene-Cell-Therapy-2025-Annual-Meeting

BUSINESSWIRE
13 May 2025

https://www.businesswire.com/news/home/20250428032612/en/Affinia-Therapeutics-to-Present-New-Data-on-its-AFTX-201-Program-in-BAG3-Dilated-Cardiomyopathy-BBB-Penetrant-AAV-Capsids-and-Proprietary-Manufacturing-Technology-at-the-28th-Annual-American-Society-of-Gene-Cell-Therapy-2025-Annual-Meeting

BUSINESSWIRE
28 Apr 2025

https://www.prnewswire.com/news-releases/affinia-therapeutics-appoints-hideo-makimura-md-phd-as-chief-medical-officer-302366862.html

PR NEWSWIRE
05 Feb 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty